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Summary: The activity of the oestradiol-17ß hydroxysteroid dehydrogenase in human endometrial and breast
cancer specimens was determined by the NAD-dependent conversion of oestradiol-17ß to oestrone. The
sensitivity of the determination was improved by the separation of the hormones by HPLC. We are now able
to determine oestradiol-17ß hydroxysteroid dehydrogenase quantitatively in cryostat sections. A clear corre-
lation of serum progesterone levels and oestradiol-17ß hydroxysteroid dehydrogenase activity in the endo-
metrium was demonstrated, and we found a more than 30-fold increase in enzyme activity after the
progesterone surge. In contrast, in breast cancer samples, we found no correlation between oestradiol-17ß
hydroxysteroid dehydrogenase and the measured serum parameters.
Introduction
The oestradiol-17ß hydroxysteroid dehydrogenase in
the human endometrium is thought to be induced
directly by progesterone during the menstrual cycle
and, therefore, is a tool in assessing progesterone
action. Additionally, oestradiol-17ß hydroxysteroid
dehydrogenase is suggested as a parameter in the
diagnosis of breast cancer by a variety of authors
(1-6).
A highly accurate method was required for the deter-
mination of very low oestradiol-17ß hydroxysteroid
dehydrogenase activities in minimal quantities of bi-
opsy tissue or in tissues such as breast cancer speci-
mens, which contain low levels of enzyme activity.
') This paper was supported by the Deutsche Forschungsge^
meinschaft, Sonderforschungsbereich 232.
2) Enzymes:
— Oestradiol-17ß hydroxysteroid dehydrogenase; (Hy-
droxysteroid-17ß: NAD+-oxidoreductase (EC 1.1.1.63)).
- Glutamate dehydrogenase (EC 1.4.1.3.)
- Alkaline phosphatase (EC 3.1.3.1.)
This would enable the investigation of possible cor-
relations between cytosolic oestrogen and progester-
one receptors and oestradiol-17ß hydroxysteroid de-
hydrogenase activity. To develop such a method, it
was firstly necessary to minimize tailings of radioac-
tive oestradiol during the Chromatographie separation
steps, and secondly to handle small quantities of tis-
sue.
Like other investigators we measured oestradiol-17ß
hydroxysteroid dehydrogenase activity by the NAD/
NADH-dependent conversion of tritiated oestradiol
to oestrone. However, we introduced HPLC for the
isolation of the reaction products, oestradiol and oes-
trone, whereas previous authors have used thin-layer
chromatography (1, 4, 7 — 9), paper chromatography
(10), hydroxyalkoxypropyl Sephadex microcolumns
(11) or lipidex microcolumns (12) for this purpose.
We approached the second problem, the determina-
tion of cytosolic receptors and oestradiol-17ß hy-
droxysteroid dehydrogenase in parallel, by determin-
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ing oestradiol-17 hydroxysteroid dehydrogenase ac-
tivity either in tissue homogenates prior to ultracen-
trifugation, or in cryostat sections of the tissue.
In the present work, we describe the use of HPLC in
the oestradiol-17 hydroxysteroid dehydrogenase as-
say procedure. The method was checked against a
standard assay in the widely examined human uterine
system (7-9, 13-15). We also describe the applica-
tion of this procedure to cryostat-sectioned material
and compare it with our standard assay procedure.
The results are relevant to the determination of oes-
tradiol-17 hydroxysteroid dehydrogenase in the dia-
gnosis of breast cancer.
Protein was determined according to the method of Bradford
(16) with human serum albumin as a standard. Prior to deter-
mination, homogenates or resuspended pellets were solubilized
in the presence of 0.3 rnpl/l KOH for 20 min at 50 °C
Preparation and incubation of cryostate sections
Duplicate sets of cryostat sections (30 μπι) to give a final section
area of about 1 cm2 were collected on small glass coverslips
and gently crushed into glass tubes containing 275 μΐ buffer
supplemented with 20 μηιοΙ/1 of oestradiol and with 0.5 μ€ί
= 18.5 kBq tritiated oestradiol (40-60 Ci/mmol = 1.5 — 2.2
TBq/mmol, NEN, Dreieichenhain). Incubation, extraction and
separation were performed as described above for the standard
assay. For protein determination the small remaining organic
phase was evaporated and the complete residue solubilized in
the presence of 0.3 mol/1 KOH.
Materials and Methods
Tissue collection and storage
Human endometrial tissue was obtained by curretage or after
hysterectomy. Human breast cancer carcinomas were obtained
immediately after surgical removal. Tissue samples freed of fat
and necrotic tissue were stored in liquid nitrogen.
Preparat ion and incubat ion of tissue homogenates
After snap freezing in liquid nitrogen the tissue was ground to
powder by three passages through a microdismembrator
(Braun, F. R. G.) with intermediate cooling in liquid nitrogen.
For oestradiol-17 hydroxysteroid dehydrogenase determina-
tion the tissue powder was diluted with 5 or 10 volumes (mg
+ μΐ) of buffer (5 mmol/l Na2HPO4, 1 mmol/1 dithiothreitol,
10 mmol/1 Na2MoO4 · 2H2O, and 115 ml/1 glycerol (87%); (pH
= 8.5). If oestrogen and gestagen receptors were to be deter-
mined as well, the dilution was performed with EORTC-buffer
(10 mmol/1 NaH2PO4, 1.5 mmol/1 EDTA, 10 mmol/l Na2MoO4
•2H2O, 115 ml/1 glycerol (87%) and 1 ml/1 monothioglycerol;
pH = 7.4). Enzyme activity was determined either directly from
the crude homogenate or after preparation of the cytosol by
ultracentrifugation from the high speed pellet (144000g) re-
suspended in buffer.
The oestradiol-17 hydroxysteroid dehydrogenase assay was
adapted from methods of Tseng & Gurpide (7), Follow et al. (8)
and King et al. (9) and always performed in duplicate or
triplicate, respectively. In brief, 6.5 nmol of oestradiol (Merck,
F.R.G.) in ethanol and 0.5 μΟί = 18.5 kBq [3H]oestradiol
(40-60 Ci/mmol = 1.5 - 2.2 TBq/mmol, NEN, Dreieichen-
hain) were evaporated to dryness and redissolved in 250 μΐ
buffer to give a final assay concentration of 20 μηιοΐ/ΐ. Then
25 μΐ homogenate or buffer as a control were added and the
reaction was started by the addition of 50 μΐ NAD (2 g/1). After
15 — 60 min of incubation at 37 °C, 10 μηιοί each of oestradiol
and oestrone were added, prior to the addition of 2.5 ml ether/
chloroform (3 -f 1, by vol.) and extraction. The aqueous phase
was reextracted with another 2.5 ml ether/chloroform and the
organic phase was evaporated to dryness and redissolved in
100 μΐ acetonitrile: water-.glacial acetic acid (38 -h 60 + 2 by
vol.) for HPLC.
For quantitation, the oestrogens were separated by a reversed
phase HPLC-technique on a 5 μηη ODS-Hypersil column (125
x 4.6 mm; Shandon, England) with the eluent described above.
The loss during extraction was estimated directly from the
oestrone added as carrier, by UV-delection or by the addition
of a [14C]oestradiol (NEN, Dreieichenhain) standard prior to
extraction.
Results
Oestradiol-17 hydroxysteroid dehydrogen-
ase activity in homogenates of the endome-
trium
In order to establish an assay for oestradiol-17 hy-
droxysteroid dehydrogenase which allows the meas-
urement of either very low enzyme activities or en-
zymatic activities in a minimal amount of tissue, it
was necessary to minimize contamination and tailing
during the separation of the enzymatieally formed
oestrone. In the reversed phase HPLC-separation de-
scribed here, the tailing of oestradiol is less than l%o.
The mean deviations in the HPLC-assay of duplicate
determinations in endometrial tissue depend on the
activity of the sample. We found deviations up to
10% for activities < 1 nmol/mg χ h (0.024-0.54
nmol/mg χ h; mainly proliferative tissue) and below
5% for activities > 1 nmol/mg χ h (1.88-9.1 nmol/
mg x h; only secretory samples).
We characterized the enzyme kinetically in homoge-
nates and found a saturating concentration of oestra-
diol of 20 μιηοΐ/ΐ and an apparent Km = 2 μιηοΐ/ΐ in
a Hanes (17) linearisation of the Michaelis-Menten
equation. Oestradiol-17 hydroxysteroid dehydrogen-
ase catalytic activity increases linearly with increasing
protein concentration, i. e. the specific activity is in-
dependent of the protein concentration in the test up
to a fourfold dilution.
Endometr ia l oestradiol-17 hydroxysteroid
dehydrogenase activity dur ing the menstrual
cycle
Oestradiol-17 hydroxysteroid dehydrogenase activ-
ity appears in significant amounts» during the second
half of the menstrual cycle aftfcf the progesterone
surge. We examined 26 individual samples in more
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than 70 duplicate determinations and found a good
correlation of the serum progesterone concentration
and the oestradiol-17ß hydroxysteroid dehydrogenase
activity in the endometrium (fig. l b, r = 0.94). It is
worth mentioning that ten tissue samples which were
affected by endometriosis also showed a correlation
of serum progesterone concentrations and oestradiol-
17ß hydroxysteroid dehydrogenase activity (data not
shown).
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A significant rise in enzymatic activity from the pro-
liferative to the secretory phase of the menstrual cycle
was apparent, although there is a considerable scatter
of the enzymatic activity from one sample to the other
(fig. 1 a). Compared with other authors we found
considerably lower enzymatic activities during the
proliferative phase, so that we noted a thirtyfold in-
crease in enzyme activity from that of the proliferative
endometrium (0.18 + 0.17nmol/mg h) to the high-
est activity measured in the mid luteal endometrium
(6.26 ± 2.8 nmol/mg h).
Determination of oestradiol-17ß hydroxysteroid de-
hydrogenase in homogenates of separate pieces of
tissue of the same uterus without a parallel histolog-
ical examination can lead to scattered results, which
are unsuitable for interpretation. For explanation see
table 1. Each sample consisted of four or five inde-
pendent pieces of tissue. After the examination of
individual pieces of tissue of either patient the results
from sample 1 appear to be rather homogeneous while
sample 2 is rather heterogeneous with respect to oes-
tradiol-17ß hydroxysteroid dehydrogenase activity.
For comparison we add the results obtained with piece
5 of the second sample in the cryostat assay.
To avoid the difficulties exemplified in table 1 it is
necessary to relate biochemical determinations to his-
tological controls. This can be achieved if oestradiol-
17ß hydroxysteroid dehydrogenase is determined
quantitatively in cryostat sections, including a histo-
logical examination of parallel sections.
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Tab. 1. Oestradiol-17ß hydroxysteroid dehydrogenase activity
in homogenates of individual samples
Sample
Piece 1
Piece 2
Piece 3
Piece 4
Piece 5
Mean
Piece 5 sections
7254
nmol/mg h
8.05
7.74
9.1
—
—8.3
—
8023
nmol/mg h
3.84
6.86
9.88
10.52
2.56*
6.73
7.36*
measured in the same piece of tissue
Fig. 1. OestradiöM7ß hydroxysteroid dehydrogenase during
the menstrual cycle:
in a) oestradiol-17p hydroxysteroid dehydrogenase ac-
tivities (nmol/mg h) of individual samples (each line
represents an individual patient) are plotted according
to the respective phase of the menstrual cycle;
b) clearly demonstrates that oestradiol-17ß hydroxy-
steroid dehydrogenase levels (nmol/mg h) in the en-
dometrium correlate well (r = 0.94, 26 patients 72 in-
dividual pieces of tissue) with serum progesterone fag/l)
levels.
Oestradiol-17ß hydroxysteroid dehydrogen-
ase activity assay in cryostat-sectioned sam-
ples
To examine and to characterize tissue samples as
completely as possible it is necessary to perform quan-
titative biochemical determinations and histology in
parallel in a single piece of tissue. To validate quan-
titative oestradiol-17ß hydroxysteroid dehydrogenase
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determinations in cryostat-sectioned material we
measured the protein content and enzyme activity in
dependence on increasing numbers of cryostat sec-
tions. We always found a linear correlation of r > 0.9
for both protein and enzyme activity, dependent on
the number of sections (fig. 2). A representative dia-
gram is shown in fig. 2; the apparent Km = 4 μιηοΐ/l
(fig. 3). The saturating concentrations of oestradiol
are about 20 μιηοΐ/ΐ and, therefore, nearly identical
in both types of experiment.
The specific oestradiol-17 hydroxysteroid dehydro-
genase activity in cryostat sections is 1.3 — 5.5 times
greater than the activities measured in homogenates.
These comparative studies which are discussed below
were performed on individual pieces of tissue cut into
two halves.
Number of sections per test tube
Fig. 2. Oestradiol-17 hydroxysteroid dehydrogenase activity
in tissue sections:
here the linear relationship of a) protein content (mg/1),
b) oestradiol-17 hydroxysteroid dehydrogenase and
the number of sections per test tube is demonstrated.
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Fig. 3. Km of oestradiol-17β hydroxysteroid dehydrogenase de-
termined in sections:
The mean Km (approx. 4 μιηοΐ/ΐ) estimated with the
section method by the Hanes linearization of the Mi-
chaelis-Menton-cqua.tion is higher than that obtained
after incubation of homogenates (2 μτηοΐ/ΐ), but it is of
comparable magnitude.
The limiting factor in determining oestradiol-17 hy-
droxysteroid dehydrogenase activity by the combir
nation of cryostat sectioning of the tissue and HPLC-
separation of the reaction products is not the enzy-
matic activity itself but the reliable determination of
the protein content. Thus, in a secretory tissue sample
we were able to determine oestradiol-17 hydroxy-
steroid dehydrogenase activity in sections of 10 —30
μιη thickness, but we needed two sections of 30 μιη
thickness of the same specimen covering about 0.5
cm2 area to get a reliable and reproducible protein
determination.
Oestradiol-17 hydroxysteroid dehydrogen-
ase in breast cancer tissue
In addition, our assay procedure should also provide
a suitable tool for the determination of relatively low
oestradiol-17 hydroxysteroid dehydrogenase activi-
ties. To prove this hypothesis we chose breast cancer
tissue which, if compared with endometrial tissue, is
expected to contain relatively low enzymatic activities.
We examined 54 tumour samples for oestradiol-17
hydroxysteroid dehydrogenase, and found activities
ranging from 0 — 32 nmol/mg χ h. The mean activity
of 30 tumour samples showing no peculiarities in the
histological examination was 0.21 ± 0.16 nmol/mg
χ h. As a control, no significant activities of oestra-
diol-17 hydroxysteroid dehydrogenase were detected
in cytosols of the tumour tissue.
We were not able to correlate oestradiol-17 hydroxy-
steroid dehydrogenase activity with progesterone- and
oestrogen receptor levels in the tissue or with lutropin,
follitropin, progesterone and oestradiol content in the
serum. However, all samples with an increased level
of oestradiol-17 hydroxysteroid dehydrogenase ac-
tivity possess some peculiarities in their histology. But
this finding is not of diagnostic value, because even
more tissue samples exist with the same peculiarities
but without increased oestradiol-17 hydroxysteroid
dehydrogenase activities.
Discussion
HPLC separation
The aim and scope of our study was to establish an
enzyme assay for either low activities of oestradiol-
17 hydroxysteroid dehydrogenase or for activities in
minimal amounts of tissue like cryostat sections or
biopsies; this would enable the determination of efi-
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zyme activity in parallel with the biochemical and/or
immunological determinations of oestrogen and pro-
gesterone receptors by concomitant histological ex-
amination. We therefore introduced HPLC to mini-
mize the tailing of oestradiol during the separation
procedure, which would otherwise interfere with the
determination of oestrone.
One problem was the internal standardisation of the
extraction procedure. To overcome this difficulty,
losses during the extraction procedure were monitored
twice, either by the UV-detection of the unlabelled
oestrone which was added as carrier and comparison
with a standard curve, or by determining the loss of
a [!4C]oestradiol standard. Both procedures have dis-
advantages. In samples with low oestradiol-17ß hy-
droxysteroid dehydrogenase activity, enzymatically
formed oestrone can be neglected in comparison with
the large excess of oestrone added as carrier. This
does not apply for activities > about 5 nmol/mg h,
when enzymatically formed oestrone interferes with
the determination of the carrier oestrone. On the other
hand, the addition of a [!4C]oestradiol standard pro-
duces the well-known difficulties of double isotope
techniques. However, the total amount of tritiated
oestradiol must be determined, to avoid the necessity
of indirect measurement. We suggest that the
[14C]standard should be omitted whenever possible.
In our view it is better to shorten the incubation
period if a crude estimate of the expected activity is
available.
Oestradiol-17ß hydroxysteroid dehydrogen-
ase in endometrial homogenates
We checked our assay system with human endometrial
tissue and compared our data with those of Tseng
and Gurpide (7, 13) and Follow et al. (8; 14). As
described above, our data for the luteal endometrium
are comparable to the findings of these authors. But
we found significantly lower activities during the pro-
liferative phase of the menstrual cycle. According to
our results there is a more than thirty-fold increase
in enzyme activity after the progesterone surge. This
is about three-fold higher than described in the liter-
ature (citations see above). We feel that these findings
are probably due to diminished background activities.
Limitations and advantages of the cryostat
section ijiethod
We found no general limitations in the determination
of the oestradiol-17ß hydroxysteroid dehydrogenase
activity in cryostat sections. As stated above, a greater
limitation is the accurate determination of the protein
content. However, we found some interference with
the determination of the enzyme activity when diffu-
sion was hindered by the overlap of two or more
sections. For this reason, sections must be arranged
carefully side by side when performing this assay.
Despite these limitations, preparation of tissue by
sectioning seems to be a very gentle procedure, as can
be deduced from the finding of about three-fold
higher enzyme activities in sections. This assumption
is further substantiated by the fact that glutamate
dehydrogenase, a mitochondrial enzyme, is increased
two-fold and alkaline phosphatase, a microsomal en-
zyme, is enriched by a factor of 1.2; oestradiol-17ß
hydroxysteroid dehydrogenase is located predomi-
nately in these two subcellular fractions (8). A great
advantage of the assay is that it provides the oppor-
tunity to correct biochemical data directly according
to histological staging.
Oestradiol-17ß hydroxysteroid dehydrogen-
ase in the diagnosis of breast cancer
We feel that oestradiol-17ß hydroxysteroid dehydro-
genase is only of very limited use in breast cancer
diagnosis, because we were not able to correlate oes-
tradiol-17ß hydroxysteroid dehydrogenase activity to
any other parameter measured, such as cytosolic oes-
trogen and progesterone receptors, or concentrations
of lutropin, follitropin, oestradiol or progesterone in
the serum. Obviously, there is no correlation with the
age of the patient. However, enriched concentrations
of oestradiol-17ß hydroxysteroid dehydrogenase
might provide evidence for accompanying anomalies,
but a specific kind of malignancy cannot be defined
by assaying oestradiol-17ß hydroxysteroid dehydro-
genase. The high oestradiol-17ß hydroxysteroid de-
hydrogenase levels which occasionally occur might in
part be explained by the findings of McNeill et al.
(18) who demonstrated that the epidermal growth
factor, the transforming growth factor and homoge-
nates of breast cancer tissue can stimulate oestradiol-
17ß hydroxysteroid dehydrogenase in adipose tissue.
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